Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Adoption of Triple Combination Therapy Accelerates at Unprecedented Rates as Precision Medicine Revolution ContinuesRockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44.94, the stock has ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

An accounting provided by Hamas over the weekend confirmed intelligence assessments, Israeli officials said. By Isabel Kershner People were trampled as pilgrims at the Maha Kumbh Mela, one of ...

U.S. President Donald Trump will pursue the "complete denuclearization of North Korea," a White House official said Tuesday, amid questions over whether Trump's recent reference to... The number of ...

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...